# Metabolic Peptide FAQ — MOTS-c, Tesamorelin, Tirzepatide — Chai Peptides

> Frequently asked questions about three Metabolic & Weight Research research peptides — MOTS-c, tesamorelin, and tirzepatide — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to MOTS-c, tesamorelin, and tirzepatide.

## What does the MOTS-c peptide do?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA that, in cell and animal research, inhibits folate-cycle enzymes to activate AMPK — a cellular energy-sensing switch — and directly binds and activates casein kinase 2 (CK2) in a tissue-specific way that improves muscle glucose uptake and helps prevent muscle atrophy in mouse models [1]. It also translocates to the cell nucleus under metabolic stress to help regulate stress-response genes [5]. No completed human trial has tested what exogenous MOTS-c does in people; the strongest human data are observational associations, such as a link between circulating MOTS-c and cardiovascular risk in hemodialysis patients [2].

## What are the negative side effects of MOTS-c?

Because no human clinical trial of exogenous MOTS-c has been completed, there is no established human side-effect profile in the peer-reviewed literature — a data gap, not a clean safety record. Everything published comes from cell and rodent studies, and the doses used in those studies (0.5-15 mg/kg/day) have no established human equivalent [3]. Research-chemical material sold for laboratory use is not regulated as a pharmaceutical, so its purity, identity, and sterility are not verified the way an approved drug's would be. This site does not describe or recommend a human dose for MOTS-c.

## Is MOTS-c legal to buy?

MOTS-c is not approved by the FDA for any human use; it is sold only as a research chemical intended for laboratory research, not human consumption. That research-use framing is a real regulatory category — it is not the same as an approved drug being legally prescribed, nor is buying a labeled research chemical automatically illegal in most jurisdictions, but no oversight body verifies what such products actually contain. Separately, anti-doping authorities such as USADA and WADA classify MOTS-c as a prohibited substance in elite sport, so competitive athletes can face sanctions for its use regardless of how it was obtained. This is regulatory and legal information, not a recommendation to purchase or use MOTS-c.

## How often do you inject MOTS-c?

There is no established human dosing schedule for MOTS-c in the peer-reviewed literature, because no completed human clinical trial has tested administering it. Published research uses daily rodent dosing regimens (0.5-15 mg/kg/day in mice and rats), which cannot be converted into a human injection frequency [3]. Chai Peptides does not provide a dosing schedule for MOTS-c or any other compound covered on this site; that is a question for a licensed clinician, and for a compound with no completed human trials, the honest answer is that the evidence needed to support any specific human schedule does not yet exist.

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone (GHRH), chemically modified to resist rapid breakdown so it can be given once daily. It is FDA-approved for one specific use: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy [7]. It works by stimulating the pituitary gland to release the body's own growth hormone in its natural pulsatile pattern, rather than supplying growth hormone directly.

## What does tesamorelin do?

In its approved population, tesamorelin reduces visceral adipose tissue — the fat stored deep around the abdominal organs — along with trunk fat and liver fat, while modestly increasing lean body mass. A 2026 meta-analysis of five randomized trials found significant reductions in all three fat measures and a significant lean-mass gain, without serious adverse events [6]. The visceral-fat effect depends on continued treatment: it re-accumulates within weeks of stopping [10].

## How does tesamorelin work?

Tesamorelin binds the growth-hormone-releasing hormone receptor on pituitary cells, triggering a signaling cascade that stimulates the body's own pulsatile growth-hormone secretion. That growth hormone drives the liver to produce IGF-1, and together GH and IGF-1 promote lipolysis with a documented preference for visceral fat over other fat depots. A study in healthy men found this raised GH and IGF-1 significantly within two weeks without meaningfully affecting fasting glucose or insulin sensitivity [9].

## Will tesamorelin help me lose belly fat?

In its studied population — adults with HIV-associated lipodystrophy — tesamorelin has repeatedly reduced visceral (deep abdominal) fat in randomized controlled trials, most recently confirmed by a 2026 meta-analysis of five pooled trials (mean difference -27.71 cm², P<0.001) [6]. That evidence is specific to lipodystrophy in the context of HIV and antiretroviral therapy; it is not the same as evidence for general-population weight loss or cosmetic fat reduction, and this site does not make that extrapolation. Tesamorelin is a prescription medicine used under a clinician's supervision, not a self-directed weight-loss regimen.

## What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two gut-hormone receptors at once — GIP and GLP-1 — making it the first approved dual incretin agonist. It is FDA-approved for type 2 diabetes mellitus, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity [12]. It is given as a once-weekly subcutaneous injection.

## How does tirzepatide work?

By engaging both the GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying — effects that together improve blood-sugar control and reduce appetite. In vitro work shows the engagement is imbalanced, favoring the GIP receptor, with biased GLP-1-receptor signaling proposed to enhance insulin secretion relative to a selective GLP-1 agonist [16]. In a head-to-head trial, this combination produced significantly greater weight loss than semaglutide, a selective GLP-1 agonist (-20.2% versus -13.7% over 72 weeks) [11].

## What does tirzepatide do in the body?

In the pancreas, it boosts glucose-dependent insulin release and suppresses inappropriate glucagon secretion. In the gut, it slows gastric emptying, extending fullness after meals (and contributing to nausea as a side effect). In the brain, it acts on hypothalamic appetite circuits to reduce hunger and food-seeking behavior — the mechanism behind the quieter 'food noise' widely described in patient exit interviews. A SURMOUNT-1 sub-analysis found roughly three-quarters of the weight lost was fat mass, with the remainder lean mass, a pattern consistent with weight loss achieved by other means [14].

## What is tirzepatide used for?

Tirzepatide's FDA-approved uses are type 2 diabetes mellitus (since May 2022), chronic weight management in adults with obesity or overweight plus a weight-related condition (since November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity [12]. In clinical research, it has also been studied directly against semaglutide, both in type 2 diabetes (SURPASS-2) [15] and in obesity (SURMOUNT-5) [11], outperforming it on weight loss in both settings.

---

An independent, citation-first read of the metabolic and weight-research literature — enthusiasm always chased with a caveat, never with a diagnosis or a dose.